Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Summit Therapeutics Plc - Stock Valuation Undemanding

- Key inflection point: topline data readout from the PhaseOut DMD phase 2 trial in Duchenne (DMD) expected in 3Q 2018
- Imminent start of a pivotal phase 3 study for ridinilazole in C. difficile infections (CDI)
- Recent Discuva acquisition reinforces novel antibiotics discovery capabilities 
- Current valuation (market cap of c. $165 mln) undemanding given the stage and commercial potential of Summit's lead programs
Summit Therapeutics Plc - Stock Valuation Undemanding

 

With approx. $42 mln in cash as of the end of October 2017, Summit looks fully funded up until the end of 2018.

Current valuation (market cap $165 mln) seems undemanding, especially vis-à-vis the $900 mln valuation of recently listed Solid Biosciences, whose lead program is just about to start clinical development.

Full report is available via Capital Network website
View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Researches

no_picture_pai.jpg
March 14 2018

OptiBiotix Health Plc (LON:OPTI) focuses on managing and treating widespread, chronic medical conditions, such as obesity and high cholesterol, through the modulation of the human microbiome.

no_picture_pai.jpg
October 17 2017

KEY INVESTOR MESSAGES

  • Commercial launch of Genedrive® Hepatitis C (HCV) test expected to start in    the coming quarters (African markets)
  • Collaboration with the US Defense Department (bio-hazard program) to generate further income in the current fiscal year
  • Re-launch of Genedrive® MTB (tuberculosis) test in India is being reassessed
  • Divestment options for the Services business are being pursued
  • Cash position of £4.2mln as of 30 September 2017
no_picture_pai.jpg
March 14 2018

A fully integrated specialty pharma company, Midatech Pharma (LON:MTPH) is rapidly progressing the development of three lead R&D programs. They have developed three proprietary drug delivery technologies (Q-Sphera, Gold Nano Particle and Nano Inclusion) to improve and expand the therapeutic potential of validated drug products. At the same time Midatech has built a US commercial unit focused on supportive care products.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use